Verena Karsten

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet · 2013 · 574 citations

Life Sciences, Biochemistry, Pharmacology +16

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Scott D. Solomon, David Adams, Arnt V. Kristen et al. · Circulation · 2019 · 461 citations

Medicine, Cardiology, Pharmacotherapy +9

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate

Tracy Zimmermann, Verena Karsten, Amy Chan et al. · Molecular Therapy · 2017 · 207 citations · Full text

Pharmacy, Pharmaceutics, Pharmacology +17

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

Bahru Habtemariam, Verena Karsten, Husain Attarwala et al. · Clinical Pharmacology & Therapeutics · 2020 · 171 citations

Medicine, Pharmacokinetics, Pharmacology +10

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

Jens Gottlieb, Martin R. Zamora, Tony N. Hodges et al. · The Journal of Heart and Lung Transplantation · 2015 · 161 citations

Medicine, Infectious Diseases, Molecular Virology +15